Publicaciones en colaboración con investigadores/as de University of Eastern Piedmont Amadeo Avogadro (26)

2023

  1. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  2. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

  3. Factors associated with the severity of COVID-19 outcomes in people with neuromuscular diseases: Data from the International Neuromuscular COVID-19 Registry

    European Journal of Neurology, Vol. 30, Núm. 2, pp. 399-412

  4. Interventional Versus Conservative Strategy in Patients with Spontaneous Coronary Artery Dissections: Insights from DISCO Registry

    Circulation: Cardiovascular Interventions, Vol. 16, Núm. 6, pp. E012780

  5. Morphological characteristics of lesions with thin cap fibroatheroma-a substudy from the COMBINE (OCT-FFR) trial

    European heart journal. Cardiovascular Imaging, Vol. 24, Núm. 5, pp. 687-693

  6. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

    eClinicalMedicine, Vol. 65

  7. Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): “Real World” Experience

    Clinical Genitourinary Cancer, Vol. 21, Núm. 5, pp. 584-593

  8. Stroke volume index and transvalvular flow rate trajectories in severe aortic stenosis treated with TAVR

    European Heart Journal Cardiovascular Imaging, Vol. 24, Núm. 8, pp. 1052-1061

  9. The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

    American Journal of Hematology, Vol. 98, Núm. 12, pp. 1856-1868

2022

  1. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

    Cancer Treatment Reviews, Vol. 111

  2. Thin-Cap Fibroatheroma Rather Than Any Lipid Plaques Increases the Risk of Cardiovascular Events in Diabetic Patients: Insights from the COMBINE OCT-FFR Trial

    Circulation: Cardiovascular Interventions, Vol. 15, Núm. 5, pp. E011728

2021

  1. Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer

    Cancers, Vol. 13, Núm. 17

  2. COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry

    Therapeutic Advances in Medical Oncology, Vol. 13

  3. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

    Leukemia, Vol. 35, Núm. 12, pp. 3444-3454

  4. Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial

    European heart journal, Vol. 42, Núm. 45, pp. 4671-4679

2020

  1. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

    Leukemia, Vol. 34, Núm. 9, pp. 2354-2363

  2. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study

    Cancer Medicine, Vol. 9, Núm. 22, pp. 8468-8479

2019

  1. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster after Autologous Stem Cell Transplantation: A Randomized Clinical Trial

    JAMA - Journal of the American Medical Association, Vol. 322, Núm. 2, pp. 123-133

  2. Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course

    Journal of Clinical Medicine, Vol. 8, Núm. 11

2018

  1. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study

    Haematologica, Vol. 103, Núm. 7, pp. 1209-1217